Saxenda Cost in California: Prices, Insurance, and Savings in 2026

What Saxenda Actually Costs at a California Pharmacy

The cash price for a 30-day supply of Saxenda at California retail pharmacies sits at $1 to 349 in 2026, matching Novo Nordisk's national list price. That buys five pre-filled pens delivering liraglutide 3 mg daily at maintenance dose. Prices do not vary much between CVS, Walgreens, and independent pharmacies across the state because this is a single-source branded biologic without a generic equivalent on the U.S. market.

Pharmacy benefit managers (PBMs) negotiate confidential rebates with Novo Nordisk, so the sticker price rarely reflects what an insured patient pays at the counter. A 2024 analysis published in JAMA Network Open found that net prices for branded GLP-1 receptor agonists averaged 40% to 60% below list after rebates (1). The problem is that those rebates flow to insurers and PBMs, not directly to patients on high-deductible plans. If you are paying cash, the number on the shelf is the number you pay.

California's Board of Pharmacy licenses 503A compounding pharmacies that can prepare liraglutide 3 mg injections under a patient-specific prescription. Compounded versions have been available since liraglutide appeared on the FDA's drug shortage list, and pricing from licensed California 503A pharmacies has ranged from roughly $150 to $450 per month depending on the compounder, concentration, and supply chain conditions. We discuss the regulatory details below.

The SCALE Obesity and Prediabetes trial (N=3,731) established the clinical basis for this price tag: participants on liraglutide 3 mg lost a mean of 8.0% of body weight at 56 weeks versus 2.6% on placebo, and 63.2% of the liraglutide group achieved at least 5% weight loss (2). Whether that outcome justifies $1,349 per month depends on your insurance situation and access to alternatives.

Does Medi-Cal Cover Saxenda?

Yes. Medi-Cal, California's Medicaid program, covers Saxenda for chronic weight management, but requires prior authorization (PA). The prescriber must document that the patient meets FDA-labeled criteria: a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia.

Medi-Cal PA criteria typically require evidence that the patient has attempted lifestyle modification (diet and exercise counseling) for at least 3 to 6 months before pharmacotherapy. Some managed care plans within Medi-Cal may also require a trial of a less expensive agent first, though specific step-therapy requirements vary by plan. The California Department of Health Care Services (DHCS) maintains the preferred drug list, and Saxenda's placement on that list determines which managed care plans include it without step edits.

Co-pays for Medi-Cal beneficiaries on Saxenda are typically $0 to $3.80 per prescription. That makes Medi-Cal one of the most affordable coverage pathways for Saxenda in the state.

A key detail: Medi-Cal coverage expanded significantly under the Affordable Care Act, and California adopted the optional Medicaid expansion population. As of 2025, California also covers undocumented adults aged 26 to 49 through full-scope Medi-Cal, potentially broadening access to covered weight-management drugs. Verify eligibility through your county's Medi-Cal office or the Covered California portal.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for patients with a BMI of 30 or greater, citing "clinically meaningful weight loss and cardiometabolic improvements" as the rationale for early intervention (3).

Commercial Insurance Coverage in California

Most large commercial insurers in California cover Saxenda, though the specifics of PA requirements, step therapy, and co-pay tiers vary considerably. Here is a general breakdown by major carrier:

Blue Shield of California and Anthem Blue Cross both include Saxenda on their formularies, typically at a Tier 3 (preferred brand) or Tier 4 (non-preferred brand) level. Expect co-pays of $50 to $150 per month on preferred plans, or co-insurance of 20% to 40% on high-deductible plans before the deductible is met.

Kaiser Permanente covers Saxenda within its integrated pharmacy system, often after documenting a BMI threshold and failed lifestyle modification. Kaiser members generally pay a fixed prescription co-pay of $30 to $75 depending on the plan tier.

Health Net and Molina Healthcare (both prominent in Medi-Cal managed care and commercial markets) require PA aligned with FDA labeling. Co-pays vary.

The Novo Nordisk savings card can reduce out-of-pocket costs for commercially insured patients to as low as $25 per month for up to 12 months. The card does not apply to government-funded insurance programs including Medi-Cal, Medicare Part D, or TRICARE. Eligible patients can enroll at the manufacturer's patient support site.

Dr. Caroline Apovian, who co-authored the Endocrine Society's obesity guideline, has stated: "Insurance coverage for anti-obesity medications remains the single largest barrier to treatment. When patients can access these drugs, adherence and outcomes improve substantially" (3).

Compounded Liraglutide 3 mg in California: Legal Status and Cost

Compounded liraglutide 3 mg is legal in California when dispensed by a 503A pharmacy operating under a valid patient-specific prescription. The California State Board of Pharmacy regulates 503A facilities under both state law (Business and Professions Code sections 4126 to 4127.2) and federal law (section 503A of the Federal Food, Drug, and Cosmetic Act).

The FDA added liraglutide to its drug shortage list due to supply constraints on Novo Nordisk's branded products. Under FDA enforcement discretion guidance for drugs on the shortage list, 503A compounders may prepare copies of commercially available drugs that would otherwise be restricted under federal law. This is the legal basis for compounded liraglutide in California and other states.

Pricing for compounded liraglutide 3 mg in California generally falls between $150 and $450 per month, depending on the pharmacy, concentration, and whether the prescription is for a 30- or 90-day supply. Some telehealth platforms that operate in California have partnered with licensed 503A compounders to offer liraglutide at the lower end of that range.

Three practical caveats apply. First, compounded liraglutide is not FDA-approved and does not carry the same regulatory assurances for potency, sterility, and stability as the branded product. The FDA has issued warning letters to specific compounders for violations. Second, if Novo Nordisk resolves the supply shortage and liraglutide is removed from the shortage list, FDA enforcement discretion could change, potentially limiting 503A compounding of this molecule. Third, insurance plans (including Medi-Cal) generally do not cover compounded drugs, so the full cost is out of pocket.

The California Board of Pharmacy maintains a license lookup tool where patients can verify that a 503A pharmacy holds a valid sterile compounding license. Checking this before filling a prescription is a reasonable precaution.

Telehealth Prescribing of Saxenda in California

California fully permits telehealth prescribing of Saxenda and other GLP-1 receptor agonists. The Medical Board of California allows prescribers to establish a patient-provider relationship through synchronous video or audio-only telehealth visits, and California law does not require an in-person visit before prescribing injectable weight-management medications.

Several telehealth platforms now operate in California and prescribe Saxenda or compounded liraglutide after an online consultation. Costs for the telehealth visit itself range from $0 (bundled into the medication price) to $99 per consultation. Patients should confirm that the prescribing clinician holds an active California medical license and that any partnered compounding pharmacy holds a valid California 503A license.

The 2023 STEP-1 extension data showed that GLP-1 receptor agonist therapy requires ongoing use to maintain weight loss: participants who discontinued semaglutide 2.4 mg regained two-thirds of lost weight within one year (4). While that trial studied semaglutide rather than liraglutide, the principle applies across the class. Long-term access (and therefore long-term affordability) matters as much as the initial fill price.

How to Get the Lowest Price on Saxenda in California

The cheapest route depends on your insurance status. Here is a decision framework:

If you have Medi-Cal: Work with your prescriber to submit prior authorization. Your co-pay will likely be $0 to $3.80 per month. This is the lowest-cost pathway.

If you have commercial insurance: Check whether your plan covers Saxenda and at what tier. Then apply the Novo Nordisk savings card to reduce co-pays. The combination of Tier 3 coverage plus the savings card can bring costs to $25 per month.

If you are uninsured or underinsured: Compare branded Saxenda cash prices (around $1,349/month) against compounded liraglutide 3 mg from a licensed California 503A pharmacy ($150 to $450/month). Pharmacy discount programs like GoodRx and RxSaver may also reduce the branded price to $900 to $1,100, though savings vary by pharmacy location.

If you are a Medicare Part D beneficiary: Saxenda coverage under Part D is inconsistent. The Medicare Prescription Drug Inflation Reduction Act capped out-of-pocket prescription costs at $2,000 per year starting in 2025, which helps if your plan covers Saxenda (5). But many Part D plans still exclude anti-obesity medications. The Treat and Reduce Obesity Act, which would mandate Medicare coverage of FDA-approved anti-obesity drugs, has been introduced in Congress multiple times but has not passed as of May 2026.

A cost-effectiveness analysis published in Annals of Internal Medicine found that liraglutide 3 mg was cost-effective at a willingness-to-pay threshold of $150,000 per quality-adjusted life year only when the drug price dropped below approximately $800 per month (6). At the current list price, the economics favor patients who can access insured or compounded pricing.

Saxenda vs. Other GLP-1 Options Available in California

Saxenda is not the only GLP-1 receptor agonist approved for weight management, and California patients have access to alternatives that may offer better efficacy or pricing.

Wegovy (semaglutide 2.4 mg) produced 14.9% mean body weight loss at 68 weeks in the STEP-1 trial (N=1,961) versus 2.4% for placebo (7). That roughly doubles Saxenda's 8.0% result from SCALE. Wegovy's list price is $1,349.02 per month, nearly identical to Saxenda. Insurance coverage patterns are similar, and Novo Nordisk offers a parallel savings card program.

Zepbound (tirzepatide) targets both GIP and GLP-1 receptors. In the SURMOUNT-1 trial (N=2,539), the 15 mg dose produced 20.9% mean weight loss at 72 weeks (8). Zepbound's list price is $1,059.87 per month, lower than Saxenda. Lilly's savings card can reduce costs to $25 per month for eligible patients.

Given these alternatives, the primary reasons a California patient might specifically choose Saxenda include: insurance formulary restrictions that cover liraglutide but not semaglutide or tirzepatide, prior successful experience with liraglutide, or clinical situations where the prescriber prefers a once-daily injection over a once-weekly injection (for example, in patients who want more granular dose titration control).

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement positions semaglutide and tirzepatide ahead of liraglutide in their obesity treatment algorithm based on weight-loss efficacy, but notes that liraglutide remains a "reasonable first-line option" when preferred agents are unavailable or not tolerated (9).

Side Effects and What California Patients Should Know Before Starting

The Saxenda FDA prescribing information reports the most common adverse reactions at the 3 mg dose as nausea (39.3%), diarrhea (20.9%), constipation (19.4%), vomiting (15.7%), and injection-site reactions (13.9%) (10). Most gastrointestinal side effects peak during dose titration (weeks 1 through 5) and decline with continued use.

Saxenda carries a boxed warning for thyroid C-cell tumors based on rodent studies. Liraglutide caused dose-dependent thyroid C-cell tumors in rats and mice at clinically relevant exposures. The relevance to humans is unknown, but Saxenda is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (10).

Dr. Robert Kushner, a professor of medicine at Northwestern University's Feinberg School of Medicine and investigator on the SCALE trials, has noted: "The dose-escalation schedule for liraglutide is designed specifically to minimize GI side effects. Patients who skip the titration or escalate too quickly are much more likely to discontinue treatment" (2).

California prescribers must document informed consent regarding the boxed warning before initiating therapy. Standard monitoring includes periodic assessment of heart rate (liraglutide increases resting heart rate by 2 to 3 beats per minute on average), renal function in patients with pre-existing kidney disease, and signs or symptoms of pancreatitis.